Global Anxiety Disorders and Depression Treatment Market USD 17.8 Billion by 2020

Global Anxiety Disorders and Depression Treatment Market USD 17.8 Billion by 2020

Anxiety disorders and depression are different, but people with depression often experience symptoms similar to those of an anxiety disorder, such as nervousness, irritability, and problems sleeping and concentrating. But each disorder has its own causes and its own emotional and behavioral symptoms.

The global anxiety disorders and depression treatment market is estimated to reach USD 17.8 Billion in 2020, growing at a CAGR of 0.9% from 2016 to 2020, according to a market research report Anxiety Disorders and Depression Treatment Market 2016-2020, published by iHealthcareAnalyst, Inc.

Visit the Anxiety Disorders and Depression Treatment Market 2016-2020 report at https://www.ihealthcareanalyst.com/report/anxiety-disorders-depression-treatment-market/

The global anxiety disorders and depression treatment market report provides market size (Revenue USD Million 2013 to 2020), market share, market trends and forecasts growth trends (CAGR%, 2016 to 2020).

The global anxiety disorders and depression treatment market segmentation is based on drug class (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake, atypical antipsychotics, tricyclic antidepressants, tetracyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, beta-blockers, anticonvulsants). The global anxiety disorders and depression treatment market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

1. Drug Class
1.1. Anticonvulsants
1.2. Atypical Antipsychotics
1.3. Benzodiazepines, Beta-Blockers
1.4. Monoamine Oxidase Inhibitors
1.5. Selective Serotonin Reuptake Inhibitors
1.6. Serotonin-Norepinephrine Reuptake
1.7. Tetracyclic Antidepressants
1.8. Tricyclic Antidepressants

2. Geography (Region, Country)
2.1 North America (U.S., Canada)
2.2 Latin America (Brazil, Mexico, Rest of LA)
2.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4 Asia Pacific (Japan, China, India, Rest of APAC)
2.5 Rest of the World

3. Company Profiles
3.1 AstraZeneca PLC
3.2 Eli Lilly and Company
3.3 Forest Laboratories, Inc.
3.4 GlaxoSmithKline plc
3.5 H. Lundbeck A/S
3.6 Johnson& Johnson
3.7 Merck & Co., Inc.
3.8 Pfizer, Inc.
3.9 Sanofi-Aventis

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: [email protected]
Website: http://www.ihealthcareanalyst.com

2016-10-23T11:28:05+00:00 Categories: Press Releases|